276 / 320
680
8. Kern K., Schebesch K., Schlaier J., Hansen E., Feigl G.,
Brawanski A., et al. Levetiracetam compared to phenytoin for
the prevention of postoperative seizures after craniotomy for
intracranial tumours in patients without epilepsy. Journal
Clinical Neuroscience. 2012; 1: 99-100.
9. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al.
Guidelines for the management of aneurysmal subarachnoid
hemorrhage: a guideline for healthcare professionals from
the American Heart Association/American Stroke Association.
Stroke. 2012;6:1711–37.
10. Pinto AN, Canhao P, Ferro JM. Seizures at the onset of
subarachnoid haemorrhage. J Neurol., 1996. 243(2):161-4.
11. Rosengart AJ, Huo JD, Tolentino J, et al. Outcome in patients
with subarachnoid hemorrhage treated with antiepileptic
drugs. J Neurosurg, 2007. 107(2):253-60.
12. Rodríguez D., Matamoros C., Fernández L., Miranda J. L.,
Pernas Y. Predictor’s of Mortality in Patients with Aneurysmal
Subarachnoid Haemorrhage and Reebleding. Neurology
Research International. Volume 2005, 6 pag.
13. Byrne J.V. Seizures after aneurysmal subarachnoid
hemorrhage treated with coil embolization. Neurosurgery,
2002. 52(3):545-51.
14. Diringer MN, Bleck TP, Claude Hemphill J III, et al. Critical care
management of patients following aneurysmal subarachnoid
hemorrhage: recommendations from the Neurocritical Care
Society’s Multidisciplinary Consensus Conference. Neurocrit
Care. 2011;2:211–40
15. Patsalos P. Drug Interactions with the Newer Antiepileptic
Drugs (AEDs)—Part 1: Pharmacokinetic and Pharmacodynamic
Interactions Between AEDs. Clin Pharmacokinet, 2013
Nov;52(11):927-66.
16. Tartara A., Galimberti C., Manni R., Parietti L., Zucca C., et
al. Differential effects of valproic acid and enzyme-inducing
anticonvulsants on nimodipine pharmacokinetics in epileptic
patients. Br J Clin Pharmacol. 1991;32:335–40.
17. Naidech A., Kreiter K., Janjua N., Ostapkovich N., Parra A.
Phenytoin Exposure Is Associated With Functional and
Cognitive Disability After Subarachnoid Hemorrhage. Stroke.
2005; 36: 583-587.
18. Chou HS, Latorre JG, Alpargu G. Outcomes after early
anticonvulsant discontinuation in aneurysmal subarachnoid
hemorrhage. J Vasc Med Surg, 2015. 3(1):1-6.
19. Dewan MC, Mocco J. Current practice regarding seizure
prophylaxis in aneurysmal subarachnoid hemorrhage across
academic centers. J Neurointerv Surg, 2015. 7(2):146-49.
20. Frey L. Epidemiology of Posttraumatic Epilepsy: A Critical
Review. Epilepsia, 44 (Suppl. 10):11–17, 2003.
21. Englander J., Cifu D., Diaz-Arrastia R. Seizures after Traumatic
Brain Injury. Arch Phys Med Rehabil. 2014 June; 95(6):
1223–1224.
22. Englander J., Bushnik T., Duong T., Cifu D., Zafonte R., Wright
J., et al. Analyzing risk factors for late posttraumtic seizures:
a prospective, mulitcenter investigation. Arch Phys Med
Rehabil. 2003; 84:365–373.
23. Chang BS, Lowenstein DH. Practice parameter: antiepileptic
drug prophylaxis in severe traumatic brain injury: report of the
Quality Standards Subcommittee of the American Academy of
Neurology. Neurology. 2003;1:10–6.
24. Temkin N., Dikmen S., Wilensky A., Keihm J., Chabal S., Winn
H., et al. A randomized, double-blind study of phenytoin for
the prevention of post-traumatic seizures. N Engl J Med.
1990; 8: 497-502.
25. Bratton S., Chestnut R., Ghajar J., et al. Guidelines for the
management of severe traumatic brain injury. XIII. Antiseizure
prophylaxis. J Neurotrauma.2007;24:S83–6.
26. Bailer
M.
Pharmacodynamic
and
pharmacokinetic
characteristics of intravenous drugs in status epilepticus.
Epilepsia, 50 (Suppl. 12): 44-48, 2009.
27. Patsalos P. N. Clinical Pharmacokinetics of Levetiracetam.
Clinical Pharmacokinet 2004; 43 (11): 707-724.
28. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated
ILAE evidence review of antiepileptic drug efficacy and
effectiveness as initial monotherapy for epileptic seizures and
syndromes. Epilepsia 2013 54:551–563.
29. Temkin N., Dikmen S., Anderson G., et al. Valproate therapy
for prevention of posttraumatic seizures: a randomized trial. J
Neurosurg. 1999; 91(4):593-600
30. Dikmen S., Machamer J., Winn H., Anderson G., Temkin N.
Neuropsychological effects of valproate in traumatic brain
injury: a randomized trial Neurology. 2000; 54(4):895-902.
31. Englot D. Epilepsy and Brain Tumors. Bergem M., Weller M.
Handbook of Clinical Neurology, Gliomas. 3rd, Amsterdam,
Elsevier, 2016: 1-464.
32. Garcés M., Villanueva V., Mauri J. A., et al. Factors influencing
response to intravenous lacosamide in emergency situations:
LACO-IV study. Epilepsy Behav. 2014 Jul;36:144-52.
33. Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors
and prognosis of refractory status epilepticus treated in a
neurological intensive care unit. J Neurol Neurosurg Psychiatry
2005;76(4):534–9.
34. Patsalos P., Berry D., Bourgeois B., et al. Antiepileptic drugs—
best practice guidelines for therapeutic drug monitoring: A
position paper by the subcommission on therapeutic drug
monitoring, ILAE Commission on Therapeutic Strategies.
Epilepsia, 49(7):1239–1276, 2008.
35. Richens A. Clinical Pharmacokinetics of Phenytoin. Clinical
Pharmacokinetics. 1979, 4: 153-169.
36. Markoula S., Teotonio R., Ratnaraj N. Lacosamide serum
concentrations in adult patients with epilepsy: the influence
of gender, age, dose, and concomitant antiepileptic drugs.
Ther Drug Monit. 2014 Aug;36(4):494-8.
37. Kane S., Bress A., Tesoro E. Characterization of Unbound
Phenytoin Concentrations in Neurointensive Care Unit
Patients Using a Revised Winter-Tozer Equation. Ann
Pharmacother. 2013 47 (5):628-36.
38. Varelas P., Spanaki M. Management of Status Epilepticus and
Critical Care Seizures. Varelas P. Seizures in Critical Care: A
Guide to Diagnosis and Therapeutics. 2ª edición, Detroit,
[REV. MED. CLIN. CONDES - 2016; 27(5) 671-681]